NEW YORK – Massive Bio and Perthera.ai on Wednesday announced a partnership aimed at matching patients to clinical trials based on molecular and genetic biomarkers.
In the partnership, the healthcare informatics firm Massive Bio will make available its artificial intelligence-powered clinical trial enrollment services. Perthera.ai will contribute its Precision Oncology Platform and Perthera Report, which are designed to interpret multiomic testing results — from sources including DNA and RNA sequencing, immunohistochemistry, and phosphoproteomics — and generate ranked treatment matches.
"By combining Perthera.ai's focus on biomarker-based algorithms with our AI-powered clinical trial matching platform, we can create more options for patients and physicians to find the best trials," Massive Bio CEO and Cofounder Selin Kurnaz said in a statement. "We can also pursue additional innovations together around real-world data, biomarker discovery, and diagnostic and commercial collaborations with industry stakeholders."